Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XTX301 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Phase 1 - XTX301 Monotherapy Dose Escalation and Pharmacodynamics Expansion | EXPERIMENTAL | Part 1A Dose Escalation of XTX301 administered in ascending doses to patients with advanced solid tumors to assess the safety and tolerability and determine/define MTD and/or the highest recommended Phase 2 dose (RP2D). Part 1B Evaluation of XTX301 in patients with selected advanced solid tumors to further characterize the pharmacodynamics profile of XTX301. |
| Phase 2 - XTX301 Monotherapy Dose Expansion in Disease-Specific Cohorts | EXPERIMENTAL | Phase 2 will further evaluate the safety and antitumor activity/efficacy of XTX301 monotherapy in disease-specific expansion cohorts of patients with select tumors, namely: * Cohort 2A: head and neck squamous cell carcinoma (HNSCC) * Cohort 2B: melanoma (patients with uveal melanoma are excluded) * Cohort 2C: non-small cell lung cancer (NSCLC) * Cohort 2D: ovarian cancer * Cohort 2E: castrate-resistant prostate cancer (CRPC)/androgen pathway modulation-resistant prostate cancer (APMR-PC) * Cohort 2F: triple-negative breast cancer (TNBC) |
| Name | Type | Description |
|---|---|---|
| XTX301 | DRUG | XTX301 monotherapy |
Inclusion Criteria: • Disease Criteria: Part 1A - Any histologically or cytologically confirmed solid tumor malignancy that is locally advanced or metastatic and has failed standard therapy, standard therapy does not confer survival benefit, or standard therapy is not available. Part 1B- Any histo...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
XTX301 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities. The drug is being studied in patients with advanced solid tumors to evaluate its safety and potential efficacy.
XTX301 targets IL-12, a cytokine involved in immune signaling. By modulating IL-12 activity, the drug aims to enhance the body's immune response against tumor cells. This mechanism is being explored in the context of advanced solid tumors, where immune activation may help control cancer growth.
XTX301 is being developed by Xilio Therapeutics, Inc., a biopharmaceutical company. Xilio Therapeutics is publicly traded under the ticker symbol XLO. The company is conducting clinical trials to evaluate the safety and efficacy of XTX301 in patients with advanced solid tumors.
XTX301 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary activity in patients with advanced solid tumors.
XTX301 is being studied in a Phase 1 clinical trial with the identifier NCT05684965. This trial, titled 'XTX301 in Patients With Advanced Solid Tumors,' is currently recruiting participants in the United States. The study aims to enroll approximately 358 patients aged 18 years and older with advanced solid tumors.
No, XTX301 is not the same as IL-12. XTX301 is a small molecule drug that targets IL-12, a cytokine involved in immune regulation. While IL-12 is a naturally occurring protein, XTX301 is a synthetic compound designed to interact with IL-12 pathways to potentially treat advanced solid tumors.